First Clinical Implantation of Endovastec™’s Hercules®-LP Thoracic Stent Graft System Completed in India

Kochi, India, 5 March 2022 - Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) has completed the first clinical implantation of its independently developed Hercules® Low Profile Thoracic Stent Graft and Delivery System (Hercules®-LP Stent Graft System) in India. This is the first product from Endovastec™ which has been approved for marketing and used in a clinical setting in India, the thirteenth market for the Hercules®-LP Stent System, following China, Brazil, Italy, the United Kingdom, and Turkey.

The first Hercules®-LP Stent System stent was successfully completed by a team led by Dr. Rohit P V Nair of Aster Medicity Hospital, Kochi. The patient was admitted into the hospital for examination due to chronic back pain and through preoperative DSA, he was diagnosed with a thoracic aortic aneurysm with a tortuous neck. After repeated studies and discussions, the surgical team selected Hercules®-LP Stent Graft System for the operation. The sheath of the delivery system is as low as 18F, which allows the stent to conform to different vascular anatomies. PET graft wrapping around the soft sheath makes it easy for the stent graft to go through the arch, and the height-mutative stent cell readily conforming to the anatomy enhances the overall flexibility. The postoperative angiography showed that the stent graft conformed well to the anatomy with the aneurysm effectively isolated.

Dr. Rohit P V Nair subsequently chose to use the Hercules®-LP Stent System for a second procedure the following day due to its excellent cross-arch capability and precise stent positioning. This patient was diagnosed by CT to have type B aortic dissection with associated complications. The hydrophilic-coated delivery sheath of Hercules®-LP Stent Graft System allowed for smooth introduction and stable release of the bare stent during the procedure. The postoperative angiography showed accurate stent positioning without migration, effective isolation of the false lumen, and good distal stent morphology.

Independently developed by Endovastec™, the Hercules®-LP Stent Graft System was approved for registration by the Central Drugs Standard Control Organization (CDSCO) in India in late 2021. As the world's fifth largest economy and the second most populous country in the world with a population of 1.4 billion people, India has a growing demand for medical technology and medical services, indicating huge market potential.

Looking ahead, Endovastec™ will continue to work with clinical experts internationally to bring more high-quality, innovative, and high-end medical devices to overseas markets, provide better medical solutions for blood circulation diseases and bring benefits to more patients with aortic and peripheral vascular diseases across the world.

About Endovastec™

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), a subsidiary of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK), was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise and the first batch of Specialized and New "Little Giant" Enterprise, AAA-level Credit Enterprise and Multinational R&D Center in China. Endovastec™ was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019. Endovastec™ is committed to provide trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping all lives, and to build a people centric enterprise ranking as a global leader of evolving and emerging medical technologies through continuous innovation.